All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

sulfadiazine silver 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anti-infectives, sulfonamides	4142	22199-08-2

Description:

Molecule	Description
Synonyms: sulfadiazine silver silvadene silver sulfadiazine sulfadiazine, silver	Antibacterial used topically in burn therapy. Molecular weight: 357.14 Formula: C10H9AgN4O2S CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 26, 1973	FDA	KING PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	248.01	18.16	153	2345	250857	50351769
PRIDE syndrome	29.23	18.16	4	2494	16	50602610
Oral lichen planus	21.22	18.16	5	2493	533	50602093
Cellulitis	20.22	18.16	21	2477	70777	50531849

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	93.15	24.97	50	1285	68356	29504836
Toxic epidermal necrolysis	90.17	24.97	33	1302	18120	29555072
Skin graft failure	28.24	24.97	5	1330	139	29573053

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	236.30	19.23	149	3223	237666	64257694
Toxic epidermal necrolysis	68.29	19.23	35	3337	37131	64458229
Cellulitis	31.21	19.23	31	3341	93626	64401734
PRIDE syndrome	29.00	19.23	4	3368	16	64495344
Skin graft failure	25.25	19.23	5	3367	221	64495139
Oral lichen planus	19.76	19.23	5	3367	676	64494684

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D06BA01	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Sulfonamides
ATC	D06BA51	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Sulfonamides
FDA CS	M0020790	Sulfonamides
FDA EPC	N0000175503	Sulfonamide Antibacterial
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Skin ulcer	indication	46742003
Burn Wound Infections	indication
Minor Bacterial Skin Infections	indication
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Superimposed infection	contraindication	193198003
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Otitis externa complicated by bacterial and fungal organisms	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Baytril Otic	Elanco US Inc.	2

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Aurora kinase A	Kinase	O14965	AURKA_HUMAN		IC50	4.68		CHEMBL
Dihydropteroate synthase	Enzyme		DHPS_ECOLI	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4018504	VUID
N0000146826	NUI
D00433	KEGG_DRUG
4018504	VANDF
C0037134	UMLSCUI
CHEBI:9142	CHEBI
CHEMBL1382627	ChEMBL_ID
441244	PUBCHEM_CID
DB05245	DRUGBANK_ID
CHEMBL439	ChEMBL_ID
W46JY43EJR	UNII
224926	RXNORM
1640	MMSL
1649	MMSL
5463	MMSL
003135	NDDF
19630009	SNOMEDCT_US
387112002	SNOMEDCT_US
D012837	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	0440-0124	CREAM	10 mg	TOPICAL	NDA	17 sections
SSD	HUMAN PRESCRIPTION DRUG LABEL	1	16590-206	CREAM	10 g	TOPICAL	NDA	14 sections
ThermazeneSilver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	21695-182	CREAM	10 mg	TOPICAL	NDA	11 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	33261-589	CREAM	10 mg	TOPICAL	NDA	16 sections
Silver Sulfadiazene	HUMAN PRESCRIPTION DRUG LABEL	1	42254-118	CREAM	10 g	TOPICAL	NDA	16 sections
SSD Cream	HUMAN PRESCRIPTION DRUG LABEL	1	43598-210	CREAM	10 g	TOPICAL	NDA	11 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	45865-642	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	49999-185	CREAM	10 g	TOPICAL	ANDA	19 sections
SILVADENE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0230	CREAM	10 mg	TOPICAL	NDA	19 sections
SILVADENE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0230	CREAM	10 mg	TOPICAL	NDA	19 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0607	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0717	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0717	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0763	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2152	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	50436-1240	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazene	HUMAN PRESCRIPTION DRUG LABEL	1	50436-3099	CREAM	10 g	TOPICAL	NDA	16 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	52959-635	CREAM	10 g	TOPICAL	NDA	14 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9090	CREAM	10 mg	TOPICAL	NDA	17 sections
Thermazene	HUMAN PRESCRIPTION DRUG LABEL	1	53097-101	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0375	CREAM	10 mg	TOPICAL	NDA	14 sections
SSD Cream	HUMAN PRESCRIPTION DRUG LABEL	1	55700-640	CREAM	10 g	TOPICAL	NDA	11 sections
SILVER SULFADIAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	59762-0131	CREAM	10 mg	TOPICAL	NDA AUTHORIZED GENERIC	21 sections
SILVADENE	HUMAN PRESCRIPTION DRUG LABEL	1	61570-131	CREAM	10 mg	TOPICAL	NDA	19 sections
SILVER SULFADIAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	61919-206	CREAM	10 mg	TOPICAL	NDA	12 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	61919-237	CREAM	10 g	TOPICAL	NDA	11 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	63187-023	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	63187-023	CREAM	10 mg	TOPICAL	NDA	17 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8768	CREAM	10 mg	TOPICAL	NDA	16 sections
Silver Sulfadiazine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8768	CREAM	10 mg	TOPICAL	NDA	16 sections